184 related articles for article (PubMed ID: 23451862)
41. Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy.
Brachat AH; Grom AA; Wulffraat N; Brunner HI; Quartier P; Brik R; McCann L; Ozdogan H; Rutkowska-Sak L; Schneider R; Gerloni V; Harel L; Terreri M; Houghton K; Joos R; Kingsbury D; Lopez-Benitez JM; Bek S; Schumacher M; Valentin MA; Gram H; Abrams K; Martini A; Lovell DJ; Nirmala NR; Ruperto N;
Arthritis Res Ther; 2017 Jan; 19(1):13. PubMed ID: 28115015
[TBL] [Abstract][Full Text] [Related]
42. Canakinumab: a review of its use in the management of systemic juvenile idiopathic arthritis.
Hoy SM
BioDrugs; 2015 Apr; 29(2):133-42. PubMed ID: 25822149
[TBL] [Abstract][Full Text] [Related]
43. Canakinumab (Ilaris) for systemic juvenile idiopathic arthritis.
Med Lett Drugs Ther; 2013 Aug; 55(1423):65-6. PubMed ID: 23959387
[No Abstract] [Full Text] [Related]
44. Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.
Feist E; Quartier P; Fautrel B; Schneider R; Sfriso P; Efthimiou P; Cantarini L; Lheritier K; Leon K; Karyekar CS; Speziale A
Clin Exp Rheumatol; 2018; 36(4):668-675. PubMed ID: 29533755
[TBL] [Abstract][Full Text] [Related]
45. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.
Ruperto N; Quartier P; Wulffraat N; Woo P; Ravelli A; Mouy R; Bader-Meunier B; Vastert SJ; Noseda E; D'Ambrosio D; Lecot J; Chakraborty A; Martini A; Chioato A;
Arthritis Rheum; 2012 Feb; 64(2):557-67. PubMed ID: 21953497
[TBL] [Abstract][Full Text] [Related]
46. [CAPS treatment].
Jiménez Treviño S; Ramos Polo E
Med Clin (Barc); 2011 Jan; 136 Suppl 1():29-33. PubMed ID: 21596184
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience.
Qiu L; Ma L; Xie Y; Jin J; Pan Y; Li S; Fan Z; Yu H
Pediatr Rheumatol Online J; 2024 Mar; 22(1):38. PubMed ID: 38504360
[TBL] [Abstract][Full Text] [Related]
48. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.
Toplak N; Blazina Š; Avčin T
Drug Des Devel Ther; 2018; 12():1633-1643. PubMed ID: 29922038
[TBL] [Abstract][Full Text] [Related]
49. Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis - data from the German AID-registry.
Lainka E; Baehr M; Raszka B; Haas JP; Hügle B; Fischer N; Foell D; Hinze C; Weissbarth-Riedel E; Kallinich T; Horneff G; Windschall D; Lilienthal E; Niehues T; Neudorf U; Berendes R; Küster RM; Oommen PT; Rietschel C; Lutz T; Weller-Heinemann F; Tenbrock K; Heubner GL; Klotsche J; Wittkowski H
Pediatr Rheumatol Online J; 2021 Mar; 19(1):38. PubMed ID: 33752669
[TBL] [Abstract][Full Text] [Related]
50. Glucocorticoids in the management of systemic juvenile idiopathic arthritis.
Vannucci G; Cantarini L; Giani T; Marrani E; Moretti D; Pagnini I; Simonini G; Cimaz R
Paediatr Drugs; 2013 Oct; 15(5):343-9. PubMed ID: 23813411
[TBL] [Abstract][Full Text] [Related]
51. Lipopolysaccharide stimulation test on cultured PBMCs assists the discrimination of cryopyrin-associated periodic syndrome from systemic juvenile idiopathic arthritis.
Wu CY; Fan WL; Chiu YM; Yang HY; Lee WI; Huang JL
Sci Rep; 2021 Jun; 11(1):11903. PubMed ID: 34099791
[TBL] [Abstract][Full Text] [Related]
52. Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases.
Topaloglu R; Batu ED; Orhan D; Ozen S; Besbas N
Pediatr Nephrol; 2016 Apr; 31(4):633-40. PubMed ID: 26563115
[TBL] [Abstract][Full Text] [Related]
53. Muckle-Wells syndrome: individualized, reflare-guided dosing of the orphan drug canakinumab.
Mueller SM; Itin P; Haeusermann P
Skinmed; 2013; 11(2):80-3. PubMed ID: 23745225
[No Abstract] [Full Text] [Related]
54. A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy.
Goh AX; Bertin-Maghit S; Ping Yeo S; Ho AW; Derks H; Mortellaro A; Wang CI
MAbs; 2014; 6(3):765-73. PubMed ID: 24671001
[TBL] [Abstract][Full Text] [Related]
55. Canakinumab for the treatment of TNF-receptor associated periodic syndrome.
La Torre F; Caparello MC; Cimaz R
Expert Rev Clin Immunol; 2017 Jun; 13(6):513-523. PubMed ID: 28454496
[TBL] [Abstract][Full Text] [Related]
56. A case of cryopyrin-associated periodic fever syndrome during canakinumab administration complicated by inflammatory bowel disease.
Yamasaki Y; Kubota T; Takei S; Imanaka H; Nonaka Y; Kawano Y
Clin Rheumatol; 2021 Jan; 40(1):393-397. PubMed ID: 32623652
[TBL] [Abstract][Full Text] [Related]
57. A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis.
Wulffraat NM
Expert Opin Drug Saf; 2015; 14(12):1961-7. PubMed ID: 26568054
[TBL] [Abstract][Full Text] [Related]
58. Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations.
Woerner A; von Scheven-Gête A; Cimaz R; Hofer M
Expert Rev Clin Immunol; 2015 May; 11(5):575-88. PubMed ID: 25843554
[TBL] [Abstract][Full Text] [Related]
59. Biomarkers in systemic juvenile idiopathic arthritis: a comparison with biomarkers in cryopyrin-associated periodic syndromes.
Nirmala N; Grom A; Gram H
Curr Opin Rheumatol; 2014 Sep; 26(5):543-52. PubMed ID: 25050926
[TBL] [Abstract][Full Text] [Related]
60. The Future of IL-1 Targeting in Kidney Disease.
Afsar B; Covic A; Ortiz A; Afsar RE; Kanbay M
Drugs; 2018 Jul; 78(11):1073-1083. PubMed ID: 29968152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
